[{"address1": "505 Odyssey Way", "city": "Merritt Island", "state": "FL", "zip": "32953", "country": "United States", "phone": "(254)244-5739", "website": "https://www.vaxxinity.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.", "fullTimeEmployees": 57, "companyOfficers": [{"maxAge": 1, "name": "Mr. Louis Garfield Reese IV", "age": 41, "title": "Co-Founder & Executive Chairman of the Board", "yearBorn": 1982, "fiscalYear": 2023, "totalPay": 275575, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mei Mei Hu J.D.", "age": 40, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1983, "fiscalYear": 2023, "totalPay": 345143, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sumita  Ray J.D.", "age": 49, "title": "Chief Legal, Compliance & Administrative Officer and Corporate Secretary", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 465557, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason  Pesile CPA, M.B.A.", "age": 50, "title": "Chief Accounting Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jean-Cosme  Dodart Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Joinnides MSE", "title": "Chief of Staff", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Manal  Morsy M.B.A., M.D., PH.D.", "title": "Chief Regulatory Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 8, "compensationRisk": 7, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.105, "open": 0.15, "dayLow": 0.105, "dayHigh": 0.15, "regularMarketPreviousClose": 0.105, "regularMarketOpen": 0.15, "regularMarketDayLow": 0.105, "regularMarketDayHigh": 0.15, "beta": 3.271, "forwardPE": -0.2631579, "volume": 15946, "regularMarketVolume": 15946, "averageVolume": 2235730, "averageVolume10days": 149238, "averageDailyVolume10Day": 149238, "bid": 0.36, "ask": 0.395, "marketCap": 12678500, "fiftyTwoWeekLow": 0.0453, "fiftyTwoWeekHigh": 2.8246, "fiftyDayAverage": 0.1715818, "twoHundredDayAverage": 0.59134346, "currency": "USD", "enterpriseValue": -2793231, "floatShares": 55619419, "sharesOutstanding": 112911000, "sharesShort": 4220918, "sharesShortPriorMonth": 3854083, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.033299997, "heldPercentInsiders": 0.50707, "heldPercentInstitutions": 0.106920004, "shortRatio": 13.97, "shortPercentOfFloat": 1.0873001, "impliedSharesOutstanding": 126785000, "bookValue": 0.106, "priceToBook": 0.9433963, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -56934000, "trailingEps": -0.45, "forwardEps": -0.38, "enterpriseToEbitda": 0.05, "52WeekChange": -0.9632353, "SandP52WeekChange": 0.2086575, "exchange": "OEM", "quoteType": "EQUITY", "symbol": "VAXX", "underlyingSymbol": "VAXX", "shortName": "Vaxxinity, Inc.", "longName": "Vaxxinity, Inc.", "firstTradeDateEpochUtc": 1636641000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a263bcbc-70bc-3371-83f5-da14e228c592", "messageBoardId": "finmb_708097952", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.1, "targetHighPrice": 15.0, "targetLowPrice": 15.0, "targetMeanPrice": 15.0, "targetMedianPrice": 15.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 30636000, "totalCashPerShare": 0.242, "ebitda": -56051000, "totalDebt": 15168000, "quickRatio": 1.764, "currentRatio": 1.888, "debtToEquity": 113.118, "returnOnAssets": -0.48341998, "returnOnEquity": -1.5064701, "freeCashflow": -37377124, "operatingCashflow": -57238000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-20"}]